Clinical Trials Logo
  1. Home
  2. Myocardial Stunning
  3. NCT04830982

Safety and Efficacy of IV Diazoxide as an Additive to Hyperkalemic Cardioplegia in Patients Undergoing Cardiac Surgery With Cardiopulmonary Bypass

Myocardial Stunning Clinical Trial

Official title:
A Randomized Placebo Controlled Single Center Phase 1 Study to Evaluate Safety and Efficacy of IV Diazoxide as an Additive to Hyperkalemic Cardioplegia in Patients Undergoing Cardiac Surgery With Cardiopulmonary Bypass

Clinical Trial Summary

This study aims to confirm the safety and efficacy of diazoxide as an additive to hyperkalemic cardioplegia in patients undergoing cardiac surgery with cardiopulmonary bypass. The investigators hypothesize that diazoxide combined with hyperkalemic cardioplegia provides superior myocardial protection and reduced myocardial stunning compared with standard cardioplegia alone. The investigators will randomize 30 patients in a 2:1 fashion to treatment vs control. Safety will be assessed by comparing mean arterial blood pressure measurements, glucose levels and incidence of adverse events between the two groups. Efficacy will be assessed by comparing right and left ventricular function in pre-operative vs post-operative transesophageal echocardiograms, need for mechanical circulatory support, ease of separation from bypass and Vasoactive Inotrope Score (VIS) between the two groups. The information gained could pave the way for the use of Katp (Potassium-atp) channel openers to prevent stunning, improve patient outcomes, and reduce health care costs related to myocardial stunning that requires inotropic and mechanical support following cardiac surgery.

Clinical Trial Description

This is a randomized blinded Phase I clinical trial. Thirty patients total will be randomized on a 2:1 basis to treatment (IV Diazoxide added to cardioplegia) vs control (cardioplegia alone). Diazoxide will be added to the first dose of cardioplegia only. Subsequent doses of cardioplegia will not contain additives. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04830982
Study type Interventional
Source Johns Hopkins University
Contact
Status Withdrawn
Phase Phase 1
Start date September 1, 2023
Completion date October 30, 2025
View Details
See also
  Status Clinical Trial Phase
Completed NCT00213746 - Evaluation of Myocardial Viability by Means of Low-dose Dobutamine Gated SPECT (the DOGS Study) N/A
Active, not recruiting NCT00123695 - Serial Echocardiography After Subarachnoid Hemorrhage N/A
Terminated NCT01500785 - Intracoronary Administration of Levosimendan in Cardiac Surgery Patients Phase 4
Completed NCT06450912 - Wall Strain Index Ratio as a Biomarker for Mechanical Complication of Hemorrhagic Myocardial Infarction
Completed NCT02545426 - Myocardial Stunning During Hemodialysis: Role of Dialyste Calcium Concentration N/A
Completed NCT01179802 - Exercise-induced Changes in Cardiac Function & Morphology N/A
Not yet recruiting NCT06308107 - Safety and Feasibility of Hyperkalemic Cardioplegia With Diazoxide in Cardiac Surgery (CPG-DZX) Trial Phase 1
Recruiting NCT04448639 - Stunning in Takotsubo Versus Acute Myocardial Infarction
Withdrawn NCT02770183 - Rate of Left Ventricular Systolic Function's Recuperation After Cardiac Surgery With Extracorporeal Circulation.
Recruiting NCT05669144 - Co-transplantation of Mesenchymal Stem Cell Derived Exosomes and Autologous Mitochondria for Patients Candidate for CABG Surgery Phase 1/Phase 2
Recruiting NCT05209230 - Is Myocardial Stunning Induced by Continuous Renal Replacement Therapy a Reality in Critically Ill Patients? N/A
Withdrawn NCT02687269 - Ranolazine a Potential New Therapeutic Application Phase 4